More concerning issues than side effects are the following:
More concerning issues than side effects are the following: (1) The durability of the vaccines, whether taken one time or in stages. If the resistance is not maintained, and the virus is still circulation, big problem. (2) The effect of those who are asymptomatic, mildly symptomatic, or adverse illness, what are the long haul effects of having the body exposed to the virus, even if successfully repelled due to natural response or immunizations. (3) Mutations on the mutations.... bound to happen with all the billion of micro sized particles. (4) What effect will the seasonal weather changes have on the current surge. Logic says, the north and central areas of country could be in deep trouble.
And while of the 50% or so have not been vaccinated, some have had it and never been tested, this is offset by the very likely of reinfections that to some degree will occur; in my opinion, the milder the infection upon initial exposure, including people who do not know it, the more likely reinfection.
On the whole, I think many experts in field are missing many questions on this.
2
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
Top 5 Most Recently Viewed Articles
Einstein Bros. Bagels Unveils Exciting Fall Flavor Fling As autumn's crisp air settles in, Einstein Bros. Bagels is thrilled to introduce a delightful seasonal treat for breakfast lovers. The new "Fall Flavor Fling" Combo offers a delicious twist on the traditional pumpkin spice, highlighting the sweet charm of maple. This limited-time combo features the scrumptious...
Continue Reading
Hisense Sets New Standards for Display Technology at CES Hisense, a prominent name in the global consumer electronics and home appliance sector, is gearing up for a remarkable presence at CES 2026. The company will unveil its theme "Innovating A Brighter Life," which underscores a commitment to creating display technologies tailored to enhance human experience. A...
Continue Reading
Understanding MicroStrategy's Market Dynamics MicroStrategy’s stock has experienced noticeable fluctuations, and as current trends indicate, it has seen significant declines, recently hovering around $155. This brings the stock down to the critical medium-term support zone of $125 to $160. An important indicator, the 13-period RSI, has fallen deep into oversold...
Continue Reading
Understanding Festi hf.’s Share Option Agreement Festi hf. has recently announced the execution of a share option agreement involving its management team. This important decision is part of the broader share option plan designed for the CEO, senior management, and key employees within the Group. Details of the Share Option Plan The share option plan was ratified at...
Continue Reading
NaaS Technology and TCC Form Dynamic Partnership for EV Solutions NaaS Technology Inc. (NASDAQ: NAAS), a pioneering EV charging service provider, has embarked on an exciting new partnership with TCC Energy Storage Technology Co., Ltd. This collaboration is set to enhance charging interconnectivity and strengthen the infrastructure of electric vehicle (EV) services. Both...
Continue Reading